<?xml version='1.0' encoding='utf-8'?>
<document id="26639454"><sentence text="CYP2C19 drug-drug and drug-gene interactions in ED patients." /><sentence text="CYP450 polymorphisms result in variable rates of drug metabolism" /><sentence text=" CYP drug-drug interactions can contribute to altered drug effectiveness and safety" /><sentence text="" /><sentence text="The primary objective was to determine the percentage of emergency department (ED) patients with cytochrome 2C19 (CYP2C19) drug-drug interactions" /><sentence text=" The secondary objective was to determine the prevalence of CYP2C19 polymorphisms in a US ED population" /><sentence text="" /><sentence text="We conducted a prospective observational study in an urban academic ED with 72,000 annual visits" /><sentence text=" Drug ingestion histories for the 48 hours preceding ED visit were obtained; each drug was coded as CYP2C19 substrate, inhibitor, inducer, or not CYP2C19 dependent" /><sentence text=" Ten percent of patients were randomized to undergo CYP2C19 genotyping using the Roche Amplichip" /><sentence text="" /><sentence text="A total of 502 patients were included; 61% were female, 65% were white, and median age was 39 years (interquartile range, 22-53)" /><sentence text=" One hundred thirty-one (26" /><sentence text="1%) patients had taken at least 1 CYP2C19-dependent home drug" /><sentence text=" Eighteen (13" /><sentence text="7%) patients who were already taking a CYP2C19-dependent drug were given or prescribed a CYP2C19-dependent drug while in the ED" /><sentence text=" Among the 53 patients genotyped, 52 (98%) were extensive metabolizers and 1 was a poor metabolizer" /><sentence text="" /><sentence text="In a population of ED patients, more than a quarter had taken a CYP2C19-dependent drug in the preceding 48 hours, but few were given or prescribed another CYP2C19-dependent drug in the ED" /><sentence text=" On genotyping analysis, CYP2C19 polymorphisms were uncommon in our cohort" /><sentence text=" We conclude that changing prescribing practice due to CYP2C19 drug-drug interaction or genotype is unlikely to be useful in most US ED populations" /><sentence text="" /></document>